Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE: Polymorphisms in the survivin

promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2009, 2:289–299.PubMed 19. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194–3200.PubMedCrossRef 20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New Selleck RG7420 guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, A-1210477 nmr National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.PubMedCrossRef 21. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP: IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration.

J Immunol 2000, 164:2769–2775.PubMed 22. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC: Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004, 10:1032–1042.PubMedCrossRef 23. Cao Q, Abeysinghe H, Chow O, Xu J, Kaung H, Fong C, Keng P, Insel RA, Lee WM, Barrett JC, Wang N: Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet 2001, 129:131–137.PubMedCrossRef 24. Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Buchler MW,

Friess H: Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic Florfenicol cancer. Mol Cancer 2005, 4:14.PubMedCrossRef 25. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD: Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 2007, 2:e392.PubMedCrossRef 26. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT: Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998, 273:51–57.PubMedCrossRef 27. Lai JP, Thompson JR, Sandhu DS, Roberts LR: Heparin-degrading learn more sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol 2008, 4:803–814.PubMedCrossRef 28. Lai JP, Sandhu DS, Shire AM, Roberts LR: The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 2008, 39:149–158.PubMedCrossRef 29. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V: HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006, 66:6025–6032.PubMedCrossRef 30.